insulin icodec/semaglutide The U.S. Food and Drug Administration has approved Novo Nordisk's Awiqli (insulin icodec-abae) subcutaneous injection, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes FDA Approves Awiqli™ (insulin icodec-abae):
Description
Eli Lilly $LLYs popular weight loss drug Zepbound has joined its competitor, Novo Nordisks Wegovy, in officially being hit by a shortage
Eating small, bland meals and adjusting injection timing helps most patients manage it
Much like diabetes or hypertension, there is guesswork involved
There can be cramping and light bleeding after the procedure
If that sounds alarmist, remember the opioid story in the US
